Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Recurrent Atypical/Malignant Meningioma
NCT04501705Phase 2Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in atypical meningioma, meningioma, sponsored by Beijing Sanbo Brain Hospital. Started Aug 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
atypical meningiomameningioma
Beyond the preview
Go deeper on NCT04501705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501705.